KURLAND FRED 4
4 · Aridis Pharmaceuticals, Inc. · Filed Jun 15, 2023
Insider Transaction Report
Form 4
KURLAND FRED
Chief Financial Officer
Transactions
- Award
Stock Options
2023-05-04+10,000→ 84,575 totalExercise: $0.16Exp: 2033-05-04→ Common Stock (10,000 underlying) - Exercise/Conversion
Restricted Stock Units
2023-06-05−4,000→ 4,000 total→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2023-06-05+4,000→ 4,000 total
Footnotes (3)
- [F1]50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F3]4,000 shares of Common Stock vested on June 5, 2023 and 4,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.